Become familiarised with pharmacodynamic drug interactions, get comprehensively informed about in vitro and vivo aspects of the ICH M12 drug interaction guidelines, build up knowledge on biomarkets for detecting clinical DDIs and hear the latest update on FDA scientific efforts.

Dr Jorg Taubel, CEO ofRichmond Pharmacology will be attending.

Latest news

The Future of Cardiometabolic Research: Five Questions Shaping the Next Decade

October 22, 2026
Cardiometabolic research is continually evolving beyond explanations centred on single causes of disease.
Read more

Upcoming Event

AASLD

05 - 09 November 2026
Richmond Pharmacology is excited to join the AASLD Emerging Topic Conference: Unified Frontiers in Liver Disease in Denver, USA, on 05– 09 November 2026.
View event